BioMérieux Receives CE Mark for Biomarker Assay for Mild TBI
BioMérieux, which signed an agreement in 2017 with Banyan Biomarkers to commercialize its TBI assay, has obtained the CE Mark for its assay to detect two biomarkers associated with mild traumatic brain injury (mTBI).
Blood Biomarkers for Detecting Brain Injury in COVID-19 Patients
COVID-19 can directly cause neurologic symptoms and long-term neurological disease.